TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
TriSalus Life Sciences (Nasdaq: TLSI) has scheduled its third quarter 2024 financial results conference call for Thursday, November 14, 2024, at 9:00 a.m. ET. The company, which focuses on improving outcomes for liver and pancreatic cancer patients through advanced delivery technology and immunotherapy, will discuss Q3 2024 results and provide a business update. The financial results press release will be issued before the call. The event will be accessible via webcast on the company's investor relations website, with a replay available afterward. Interested parties can register online to receive dial-in details.
TriSalus Life Sciences (Nasdaq: TLSI) ha programmato la sua conferenza sui risultati finanziari del terzo trimestre 2024 per giovedì 14 novembre 2024, alle 9:00 ET. L'azienda, che si concentra sul miglioramento dei risultati per i pazienti affetti da cancro al fegato e al pancreas attraverso tecnologie di somministrazione avanzate e immunoterapia, discuterà i risultati del Q3 2024 e fornirà un aggiornamento sulle attività. Il comunicato stampa sui risultati finanziari sarà emesso prima della chiamata. L'evento sarà accessibile tramite webcast sul sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile successivamente. Le parti interessate possono registrarsi online per ricevere i dettagli per la chiamata.
TriSalus Life Sciences (Nasdaq: TLSI) ha programado su conferencia de resultados financieros del tercer trimestre de 2024 para el jueves 14 de noviembre de 2024, a las 9:00 a.m. ET. La empresa, que se enfoca en mejorar los resultados para pacientes con cáncer de hígado y páncreas a través de tecnología de entrega avanzada e inmunoterapia, discutirá los resultados del Q3 2024 y ofrecerá una actualización del negocio. El comunicado de prensa sobre los resultados financieros se emitirá antes de la llamada. El evento será accesible a través de un webcast en el sitio web de relaciones con inversores de la empresa, con una repetición disponible posteriormente. Las partes interesadas pueden registrarse en línea para recibir los detalles de conexión.
TriSalus Life Sciences (Nasdaq: TLSI)는 2024년 3분기 재무 결과 발표 컨퍼런스 콜을 2024년 11월 14일 목요일 오전 9시(동부 표준시)로 예정하였습니다. 간 및 췌장암 환자의 치료 결과 개선에 중점을 두고 있는 이 회사는 2024년 3분기 결과를 논의하고 사업 업데이트를 제공합니다. 재무 결과에 관한 보도자료는 콜 전에 발행될 예정입니다. 이 이벤트는 회사의 투자자 관계 웹사이트에서 웹캐스트를 통해 접근 가능하며, 이후 재생이 가능합니다. 관심 있는 개인은 전화 회의 세부정보를 받기 위해 온라인으로 등록할 수 있습니다.
TriSalus Life Sciences (Nasdaq: TLSI) a programmé sa conférence téléphonique sur les résultats financiers du troisième trimestre 2024 pour le jeudi 14 novembre 2024, à 9h00 ET. L'entreprise, qui se concentre sur l'amélioration des résultats pour les patients atteints de cancer du foie et du pancréas grâce à une technologie de livraison avancée et à l'immunothérapie, discutera des résultats du T3 2024 et fournira une mise à jour sur les activités. Le communiqué de presse sur les résultats financiers sera publié avant l'appel. L'événement sera accessible par webcast sur le site web des relations investisseurs de l'entreprise, avec une rediffusion disponible par la suite. Les parties intéressées peuvent s'inscrire en ligne pour recevoir les détails de connexion.
TriSalus Life Sciences (Nasdaq: TLSI) hat seine Telefonkonferenz zu den Finanzergebnissen des dritten Quartals 2024 für Donnerstag, den 14. November 2024, um 9:00 Uhr ET geplant. Das Unternehmen, das sich darauf konzentriert, die Ergebnisse für Patienten mit Leber- und Bauchspeicheldrüsenkrebs durch fortschrittliche Abgabetechnologie und Immuntherapie zu verbessern, wird die Ergebnisse des Q3 2024 diskutieren und ein Update zur Geschäftslage geben. Die Pressemitteilung zu den Finanzergebnissen wird vor dem Call veröffentlicht. Die Veranstaltung wird über einen Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die anschließend verfügbar ist. Interessierte Parteien können sich online registrieren, um die Einwahldaten zu erhalten.
- None.
- None.
Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET
The event will be webcast live on the investor relations section of TriSalus’ website at https://investors.trisaluslifesci.com/news-events/events-presentations. A replay will also be available on the website following the event. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.
The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD method are commonly present as well. Nelitolimod delivered by the PEDD method will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031384321/en/
For Media Inquiries:
Stephanie Jacobson
Argot Partners
610.420.3049
TriSalus@argotpartners.com
For Investor Inquiries:
James Young
SVP-Investor Relations/Treasurer
847.337.0655
james.young@trisaluslifesci.com
Source: TriSalus Life Sciences
FAQ
When will TriSalus Life Sciences (TLSI) report Q3 2024 earnings?
How can I access TriSalus Life Sciences (TLSI) Q3 2024 earnings call?
Will there be a replay available for TriSalus Life Sciences (TLSI) Q3 2024 earnings call?
